Skyrizi

Business

AbbVie's Valuation Crossroads: Short-Term Volatility Meets Long-Term Strength

AbbVie's stock presents a complex picture for investors, with recent mixed performance contrasting sharply with its robust multi-year returns. As shares trade below consensus targets, the market weighs near-term headwinds against the pharmaceutical giant's proven track record and pipeline potential.

Business

Beyond Humira: How AbbVie Plans to Reign as a Biopharma Powerhouse by 2031

With its blockbuster Humira era in the rearview, AbbVie is betting big on its next-generation immunology drugs and a deep pipeline to drive growth and maintain its crown among Dividend Kings.

Business

Biotech Showdown: Can Upstart Abivax Challenge Pharma Giant AbbVie in Immunology Race?

Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.